Media coverage about KemPharm (NASDAQ:KMPH) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. KemPharm earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 45.9540862439847 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news articles that may have effected Accern’s analysis:

A number of research analysts recently weighed in on the stock. Zacks Investment Research raised shares of KemPharm from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. ValuEngine raised shares of KemPharm from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd. Oppenheimer Holdings, Inc. set a $13.00 target price on shares of KemPharm and gave the company a “buy” rating in a research report on Thursday, August 10th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $7.00 target price on shares of KemPharm in a research report on Monday, September 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. KemPharm has a consensus rating of “Buy” and an average price target of $9.00.

KemPharm (NASDAQ:KMPH) remained flat at $$3.80 during trading on Tuesday. 18,610 shares of the company’s stock were exchanged, compared to its average volume of 28,791. KemPharm has a twelve month low of $2.45 and a twelve month high of $5.40. The company has a debt-to-equity ratio of -2.34, a current ratio of 8.40 and a quick ratio of 8.40.

KemPharm (NASDAQ:KMPH) last released its earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.19. equities analysts forecast that KemPharm will post -2.7 EPS for the current year.

In other news, major shareholder Delaware Street Capital Master acquired 325,888 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was bought at an average price of $3.27 per share, with a total value of $1,065,653.76. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. In the last three months, insiders bought 335,188 shares of company stock valued at $1,090,088. Insiders own 25.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/07/kempharm-kmph-receives-daily-news-sentiment-score-of-0-09.html.

KemPharm Company Profile

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Insider Buying and Selling by Quarter for KemPharm (NASDAQ:KMPH)

Receive News & Stock Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related stocks with our FREE daily email newsletter.